New indication for Opdivo helps repair damage from AZ trial failure fallout

1 August 2017
2019_biotech_test_vial_discovery_big

New York-based Bristol-Myers Squibb (NYSE: BMY) has received approval from the US Food and Drug Administration for Opdivo (nivolumab) in a new indication.

The immunotherapy may now be marketed as a treatment for adult and pediatric patients with certain kinds of colorectal cancer that have progressed despite treatment.

The approval was given under the agency’s accelerated approval based on clinical data from the CheckMate trial, related to overall response rate and duration of response. Continued approval may depend on confirmatory trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology